Brain tumors and circulating micrornas: a systematic review and diagnostic meta-analysis

Aalami, Amir Hossein; Abdeahad, Hossein; Shoghi, Ali; Mesgari, Mohammad; Amirabadi, Amir; Sahebkar, Amirhossein

doi:10.1080/14737159.2022.2019016

Cited by 16 publications

(7 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The global older society is another factor driving the market for brain tumor diagnostics. According to the American Cancer Society, there were approximately 79 000 new primary tumor diagnoses in 2019, with around ∼1% (or roughly 23 880) of them being malignant [13][14][15]. The WHO revised its categorization of CNS malignancies in 2021, which includes gliomas.…”

Section: Current Diagnostics and Treatment Strategies For Gbmmentioning

confidence: 99%

See 1 more Smart Citation

Recent advancements and theranostics strategies in glioblastoma therapy

Baddam,

Kalagara,

Kuna

et al. 2023

Biomed. Mater.

View full text Add to dashboard Cite

Glioblastoma (GBM) is the most aggressive and lethal malignant brain tumour, and it is challenging to cure with surgery and treatment. The prevention of permanent brain damage and tumour invasion, which is the ultimate cause of recurrence, are major obstacles in GBM treatment. Besides, emerging treatment modalities and newer genetic findings are helping to understand and manage GBM in patients. Accordingly, researchers are focusing on advanced nanomaterials-based strategies for tackling the various problems associated with GBM. In this context, researchers explored novel strategies with various alternative treatment approaches such as early detection techniques and theranostics approaches. In this review, we have emphasized the recent advancement of GBM cellular models and their roles in designing GBM therapeutics. We have added a special emphasis on the novel genetic and drug target findings as well as strategies for early detection. Besides, we have discussed various theranostic approaches such as hyperthermia therapy, phototherapy and image-guided therapy. Approaches utilized for targeted drug delivery to the GBM were also discussed. This article also describes the recent in vivo, in vitro and ex vivo advances using innovative theranostic approaches.

show abstract

Section: Current Diagnostics and Treatment Strategies For Gbmmentioning

confidence: 99%

“…The cytological heterogeneity of GBM makes complete eradication difficult due to the invasion of remaining cancer cells in the parenchyma. After surgical cytoreduction, infiltrative cells invariably survive, leading to recurrence [13,23].…”

Section: Current Challenges In Gbm Diagnosticsmentioning

confidence: 99%

Recent advancements and theranostics strategies in glioblastoma therapy

Baddam,

Kalagara,

Kuna

et al. 2023

Biomed. Mater.

View full text Add to dashboard Cite

show abstract

“…Additionally, we will describe effective epigenetic drugs explorable for the treatment of GBM. As the role of noncoding RNAs has been extensively and recently reviewed elsewhere, [5][6][7] we will focus, in particular, on the relevance of DNA and histone modifications in glioblastoma diagnosis, prognosis and therapy.…”

Section: Introductionmentioning

confidence: 99%

Epigenetic alterations in glioblastomas: Diagnostic, prognostic and therapeutic relevance

Montella¹,

Cuomo

Gaudio

et al. 2022

Intl Journal of Cancer

View full text Add to dashboard Cite

Glioblastoma, the most common and heterogeneous tumor affecting brain parenchyma, is dismally characterized by a very poor prognosis. Thus, the search of new, more effective treatments is a vital need. Here, we will review the druggable epigenetic features of glioblastomas that are, indeed, currently explored in preclinical studies and in clinical trials for the development of more effective, personalized treatments. In detail, we will review the studies that have led to the identification of epigenetic signatures, IDH mutations, MGMT gene methylation, histone modification alterations, H3K27 mutations and epitranscriptome landscapes of glioblastomas, in each case discussing the corresponding targeted therapies and their potential efficacy. Finally, we will emphasize how recent technological improvements permit to routinely investigate many glioblastoma epigenetic biomarkers in clinical practice, further enforcing the hope that personalized drugs, targeting specific epigenetic features, could be in future a therapeutic option for selected patients.

show abstract

“…Cancer-associated miRNA signatures have been reported for gliomas [25], breast cancer [26], melanoma [27], lung cancer [28], hepatocarcinoma [29], gastric cancer [30], and other types of tumors [31][32][33]. Most of them are designed for early diagnostic purposes, while others are used to identify prognostic markers; limited data are available on the possibility that miRNAs found to be dysregulated in the bloodstream may be also therapeutic targets.…”

Section: Introductionmentioning

confidence: 99%

MicroRNAs miR-584-5p and miR-425-3p Are Up-Regulated in Plasma of Colorectal Cancer (CRC) Patients: Targeting with Inhibitor Peptide Nucleic Acids Is Associated with Induction of Apoptosis in Colon Cancer Cell Lines

Gasparello

Papi

Zurlo

et al. 2022

Cancers

View full text Add to dashboard Cite

Liquid biopsy has dramatically changed cancer management in the last decade; however, despite the huge number of miRNA signatures available for diagnostic or prognostic purposes, it is still unclear if dysregulated miRNAs in the bloodstream could be used to develop miRNA-based therapeutic approaches. In one author’s previous work, nine miRNAs were found to be dysregulated in early-stage colon cancer (CRC) patients by NGS analysis followed by RT-dd-PCR validation. In the present study, the biological effects of the targeting of the most relevant dysregulated miRNAs with anti-miRNA peptide nucleic acids (PNAs) were verified, and their anticancer activity in terms of apoptosis induction was evaluated. Our data demonstrate that targeting bloodstream up-regulated miRNAs using anti-miRNA PNAs leads to the down-regulation of target miRNAs associated with inhibition of the activation of the pro-apoptotic pathway in CRC cellular models. Moreover, very high percentages of apoptotic cells were found when the anti-miRNA PNAs were associated with other pro-apoptotic agents, such as sulforaphane (SFN). The presented data sustain the idea that the targeting of miRNAs up-regulated in the bloodstream with a known role in tumor pathology might be a tool for the design of protocols for anti-tumor therapy based on miRNA-targeting molecules.

show abstract

Brain tumors and circulating micrornas: a systematic review and diagnostic meta-analysis

Cited by 16 publications

References 62 publications

Recent advancements and theranostics strategies in glioblastoma therapy

Recent advancements and theranostics strategies in glioblastoma therapy

Epigenetic alterations in glioblastomas: Diagnostic, prognostic and therapeutic relevance

MicroRNAs miR-584-5p and miR-425-3p Are Up-Regulated in Plasma of Colorectal Cancer (CRC) Patients: Targeting with Inhibitor Peptide Nucleic Acids Is Associated with Induction of Apoptosis in Colon Cancer Cell Lines

Contact Info

Product

Resources

About